Latest News & Updates
Breaking News
18 hours ago
Simantini Singh Deo
Other trending news you may like to read
Ipsen Acquires Kartos Therapeutics to Add Phase III MDM2 Inhibitor Navtemadlin to Oncology Pipeline
Ipsen acquires Kartos Therapeutics, adding Phase III MDM2 inhibitor navtemadlin with a potential 2028 approval target in myelofibrosis.
Simantini Singh Deo
Strides Pharma Divests Majority Stake in Pivot Path in Rs. 100 Crore Deal
Strides Pharma sells majority stake in Pivot Path for Rs. 100 crore, signalling portfolio consolidation toward regulated-market manufacturing.
Simantini Singh Deo
Roche Launches AXELIOS 1 Next-Generation Sequencing Platform Powered by Proprietary SBX Technology
Roche launches AXELIOS 1, an SBX-powered sequencing platform offering same-day whole-genome results with implications for pharma genomic QC workflows.
Simantini Singh Deo
AB Science Achieves 67% ORR in Phase 1 Step 3 of AB8939 Plus Venetoclax for Relapsed AML
AB Science reports 67% ORR and 100% DCR in Phase 1 Step 3 of AB8939 plus venetoclax in adverse-risk relapsed/refractory AML.
Simantini Singh Deo
